• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞癌的生存率是否在提高?一项基于人群的研究,探讨了 20 世纪 90 年代和 21 世纪初肝细胞癌患者的生存率。

Is survival for hepatocellular carcinoma increasing? A population-based study on survival of hepatocellular carcinoma patients in the 1990s and 2000s.

机构信息

Department of Global Public Health, Karolinska Institutet, Solnavägen 1 E, 11365 Stockholm, Sweden.

Surgical Clinic, Department of Clinical and Experimental Sciences, University of Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy.

出版信息

Clin Res Hepatol Gastroenterol. 2021 Jan;45(1):101433. doi: 10.1016/j.clinre.2020.04.004. Epub 2020 May 12.

DOI:10.1016/j.clinre.2020.04.004
PMID:32409284
Abstract

BACKGROUND

Improvement of survival rates for hepatocellular carcinoma during the last two decades and related factors are still debated. This study aimed to evaluate the risk of death and the role of prognostic factors in patients with hepatocellular carcinoma diagnosed in 1995-2001 and 2004-2006.

METHODS

We performed univariate and multivariable survival analyses of subjects with a first hepatocellular carcinoma diagnosis in 1995-2001 and in 2004-2006, all residing in Brescia province, Italy. Mediation analysis of treatment role in survival was conducted.

RESULTS

During follow-up (median 21.1 months) 913 subjects died (95.5%). The 1-, 3- and 5-year survival rates were higher for cases diagnosed in 2004-2006 (64.4%, 35.9% and 24.3%) than in 1995-2001 (60.8%, 34.5% and 20.7%). T stage, metastasis, cirrhosis, Child-Pugh class, portal vein invasion, serum creatinine level, treatment approach and diabetes were survival predictors in both periods. Patients with diagnosis in 2004-2006 had 36% lower risk of death than those with diagnosis in 1995-2001 using adjusted Cox proportional hazard model. The association between diagnosis period and risk of death was mediated by changes in treatment approach.

CONCLUSION

We observed a decreased risk of death for first hepatocellular carcinoma diagnosis from 2004-2006 to 1995-2001, which was partially attributable to improvements in treatment approach.

摘要

背景

在过去的二十年中,肝细胞癌的生存率得到了提高,相关因素仍存在争议。本研究旨在评估 1995-2001 年和 2004-2006 年诊断的肝细胞癌患者的死亡风险和预后因素的作用。

方法

我们对 1995-2001 年和 2004-2006 年首次诊断为肝细胞癌的患者进行了单因素和多因素生存分析,所有患者均居住在意大利布雷西亚省。对治疗在生存中的作用进行了中介分析。

结果

在随访期间(中位 21.1 个月),913 例患者死亡(95.5%)。2004-2006 年诊断的病例的 1、3 和 5 年生存率分别为 64.4%、35.9%和 24.3%,高于 1995-2001 年的 60.8%、34.5%和 20.7%。T 分期、转移、肝硬化、Child-Pugh 分级、门静脉侵犯、血清肌酐水平、治疗方法和糖尿病是两个时期的生存预测因素。调整后的 Cox 比例风险模型显示,2004-2006 年诊断的患者死亡风险比 1995-2001 年诊断的患者低 36%。诊断期与死亡风险之间的关联部分由治疗方法的变化介导。

结论

我们观察到,2004-2006 年首次诊断为肝细胞癌的患者死亡风险较 1995-2001 年有所降低,这部分归因于治疗方法的改进。

相似文献

1
Is survival for hepatocellular carcinoma increasing? A population-based study on survival of hepatocellular carcinoma patients in the 1990s and 2000s.肝细胞癌的生存率是否在提高?一项基于人群的研究,探讨了 20 世纪 90 年代和 21 世纪初肝细胞癌患者的生存率。
Clin Res Hepatol Gastroenterol. 2021 Jan;45(1):101433. doi: 10.1016/j.clinre.2020.04.004. Epub 2020 May 12.
2
Hepatocellular carcinoma invading the main portal vein: treatment with transcatheter arterial chemoembolization and portal vein stenting.肝细胞癌侵犯门静脉主干:经导管动脉化疗栓塞及门静脉支架置入治疗
Cardiovasc Intervent Radiol. 2009 Jan;32(1):52-61. doi: 10.1007/s00270-008-9454-x. Epub 2008 Oct 18.
3
Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.与经动脉化疗栓塞术或索拉非尼相比,肝切除术治疗伴有门静脉癌栓的肝细胞癌的生存结局。
Clin Mol Hepatol. 2016 Mar;22(1):160-7. doi: 10.3350/cmh.2016.22.1.160. Epub 2016 Mar 28.
4
Outcome and prognostic factors of spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization.经动脉栓塞治疗自发性破裂肝细胞癌的疗效及预后因素
Acta Radiol. 2011 Apr 1;52(3):331-5. doi: 10.1258/ar.2010.100369. Epub 2011 Mar 3.
5
Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.经肝动脉化疗栓塞联合索拉非尼治疗巴塞罗那临床肝癌分期 B 期和 C 期后的生存预后因素。
Acad Radiol. 2018 Apr;25(4):423-429. doi: 10.1016/j.acra.2017.10.018. Epub 2017 Nov 29.
6
Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.经动脉化疗栓塞联合微波消融治疗肝细胞癌后生存的预后因素
World J Gastroenterol. 2014 Dec 14;20(46):17483-90. doi: 10.3748/wjg.v20.i46.17483.
7
Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion.经动脉重复化疗栓塞术治疗门静脉侵犯型肝细胞癌的再评估
J Gastroenterol Hepatol. 2009 May;24(5):806-14. doi: 10.1111/j.1440-1746.2008.05728.x. Epub 2009 Jan 13.
8
Hepatocellular carcinoma in Lebanon: Etiology and prognostic factors associated with short-term survival.黎巴嫩的肝细胞癌:与短期生存相关的病因及预后因素
World J Gastroenterol. 2006 Jun 14;12(22):3575-80. doi: 10.3748/wjg.v12.i22.3575.
9
Vascular Invasion and Metastasis is Predictive of Outcome in Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma.血管侵犯和转移可预测巴塞罗那临床肝癌分期 C 期肝细胞癌的结局。
J Natl Compr Canc Netw. 2017 Feb;15(2):197-204. doi: 10.6004/jnccn.2017.0020.
10
Transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis: prognostic factors in a single-center study of 188 patients.经动脉化疗栓塞术治疗伴有门静脉癌栓的晚期肝细胞癌:一项纳入188例患者的单中心研究中的预后因素
Biomed Res Int. 2014;2014:194278. doi: 10.1155/2014/194278. Epub 2014 Apr 8.

引用本文的文献

1
Single cell analysis and bioinformatics reveal pyroptosis mechanisms in hepatocellular carcinoma.单细胞分析与生物信息学揭示肝细胞癌中的细胞焦亡机制。
Discov Oncol. 2025 Jun 14;16(1):1096. doi: 10.1007/s12672-025-02907-3.
2
Radiomics as a tool for prognostic prediction in transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.基于放射组学的经动脉化疗栓塞术治疗肝细胞癌的预后预测工具:系统评价和荟萃分析。
Radiol Med. 2024 Aug;129(8):1099-1117. doi: 10.1007/s11547-024-01840-9. Epub 2024 Jul 26.
3
Unveiling the flames: macrophage pyroptosis and its crucial role in liver diseases.
揭示火焰:巨噬细胞焦亡及其在肝脏疾病中的关键作用。
Front Immunol. 2024 Feb 6;15:1338125. doi: 10.3389/fimmu.2024.1338125. eCollection 2024.
4
ULK1 Depletion Protects Mice from Diethylnitrosamine-Induced Hepatocarcinogenesis by Promoting Apoptosis and Inhibiting Autophagy.ULK1缺失通过促进凋亡和抑制自噬保护小鼠免受二乙基亚硝胺诱导的肝癌发生。
J Hepatocell Carcinoma. 2023 Feb 27;10:315-325. doi: 10.2147/JHC.S399855. eCollection 2023.
5
The Immunoregulatory Effect of Aconite Treatment on H22 Tumor-Bearing Mice via Modulating Adaptive Immunity and Natural Killer-Related Immunity.附子治疗对荷H22肿瘤小鼠通过调节适应性免疫和自然杀伤相关免疫的免疫调节作用
Evid Based Complement Alternat Med. 2023 Jan 30;2023:1481114. doi: 10.1155/2023/1481114. eCollection 2023.
6
Poly(ADP-Ribose) Polymerase Inhibition as a Promising Approach for Hepatocellular Carcinoma Therapy.聚(ADP-核糖)聚合酶抑制作为肝细胞癌治疗的一种有前景的方法。
Cancers (Basel). 2022 Aug 5;14(15):3806. doi: 10.3390/cancers14153806.
7
Expression of Cellular and Extracellular , and in Hepatocellular Carcinoma.细胞内和细胞外基质、和在肝细胞癌中的表达。
Int J Mol Sci. 2022 May 31;23(11):6183. doi: 10.3390/ijms23116183.
8
Single-Shot Local Injection of Microfragmented Fat Tissue Loaded with Paclitaxel Induces Potent Growth Inhibition of Hepatocellular Carcinoma in Nude Mice.单次局部注射负载紫杉醇的微片段化脂肪组织可有效抑制裸鼠肝细胞癌的生长。
Cancers (Basel). 2021 Nov 2;13(21):5505. doi: 10.3390/cancers13215505.